优福定（UFT）治疗肾细胞癌的临床研究
[Clinical study of UFT in renal cell carcinoma].
作者信息
Masuda F, Suzuki M, Ohnishi T, Nakada J, Mori Y, Iizuka N, Machida T
出版信息
Gan To Kagaku Ryoho. 1985 Feb;12(2):325-30.
A clinical study of UFT, a mixture of FT and uracil in a molar ratio of 1 : 4, was conducted on 12 patients with renal cell carcinoma. UFT was continuously administered at doses of 300, 400 or 600 mg per day. CR was recorded in 2 patients, PR in 2, NC in 7 and PD in 2, respectively. The overall response rate was 33.3%. Concerning side effects, 2 of the 12 patients suffered from anorexia and stomatitis, but no hepatic disorders or bone marrow suppression was observed. We concluded that UFT therapy was effective for renal cell carcinoma.
对12例肾细胞癌患者进行了优福定（FT与尿嘧啶摩尔比为1:4的混合物）的临床研究。优福定以每日300、400或600毫克的剂量持续给药。分别有2例患者达到完全缓解（CR），2例部分缓解（PR），7例疾病稳定（NC），2例疾病进展（PD）。总缓解率为33.3%。关于副作用，12例患者中有2例出现厌食和口腔炎，但未观察到肝脏疾病或骨髓抑制。我们得出结论，优福定治疗对肾细胞癌有效。
Zotero 插件